Suven Life Sciences Ltd - SUVEN LIFE SCIE. Share Price

Sector: Pharmaceuticals | ISIN: INE495B01038
₹ 111.85 (-0.09%) icon16 Apr, 2024, 12:00:00 AM

Suven Life Sciences Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/16/2024 12:00:00 AM

    ₹ 111.85 -0.10 -0.09
  • Open
  • ₹ 111
  • Prev. Close
  • ₹ 111.95
  • Turnover(Lac.)
  • ₹ 134
  • Day's High
  • ₹ 115.55
  • Day's Low
  • ₹ 107.35
  • 52 Week's High
  • ₹ 129
  • 52 Week's Low
  • ₹ 55
  • Book Value
  • ₹ 38.91
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 2,439.15
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

Suven Life Sciences Ltd Corporate Actions

Suven Life Sciences Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

18 April , 2024 | 07:38 AM

ad IconAd Image

Suven Life Sciences Ltd FINANCIALS

No Data Available To Display Chart

Suven Life Sciences Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Suven Life Sciences Ltd

  • Venkateswarlu Jasti
  • Chairman & CEO
  • Sudha Rani Jasti
  • Whole-time Director
  • Seyed E Hasnain
  • Director
  • M Gopalakrishna
  • Independent Director
  • Santanu Mukherjee
  • Independent Director
  • J A S Padmaja
  • Independent Director
  • Shrenik Soni
  • Company Sec. & Compli. Officer


Suven Life Sciences Limited, erstwhile Suven Pharmaceuticals (SPL), is in the business of Contract Research And Manufacturing Services (CRAMS, catering to the needs of global life science industry and fine chemical majors. Suvens CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The company services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business. The Company has two international wholly owned subsidiary companies and one Indian wholly owned subsidiary company as on 31st March 2019. Suven Life Sciences Limited began operations in 1989 as specialty chemicals provider. Incorporated in Mar.89 as a private limited company, Suven Pharmaceuticals (SPL) was converted into a public limited company in Jan.95. It was promoted by Sudharani Jasti and Venkateswarlu Jasti, who is the present Chairman & CEO of the company. In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the companys project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. During 1999-2000, the company... Read More

Reports by Suven Life Sciences Ltd

Reports by Suven Life Sciences Ltd

Company FAQ

No Record Found